XM does not provide services to residents of the United States of America.
On May 7th XM hosted its latest free seminar in the city of Shenzhen, China, entitled Introduction to Avramis Swing Trading.
The event was held on the premises of The Westin Shenzhen Nanshan Hotel, where forex instructor Marios Pashardes, who is an accomplished seminar speaker, delivered a captivating presentation on the various aspects of swing trading, emphasizing the importance of technical analysis methods that can be applied to identify price trends.
The intensive seminar, designed to suit the needs of both beginner and more advanced traders, consisted of a morning and an afternoon session, guiding participants through a systematic approach to the use of charts, price patterns, multiple time frames and last but not least the use of Fibonacci. The strategy called Avramis Trend Reversal was also demonstrated to the audience for a better understanding of how entry and exit points can be planned more efficiently, along with proper risk management.
All our clients present at the seminar also had the chance to enter the XM Lucky Draw and go for valuable cash prizes worth 3,000 USD. The raffle draw took place at the venue.
The MT4 accounts of the winners of the 3,000 USD are as follows:
Prizes | MT4 Accounts |
Grand Prize: 1 x 700 USD Cash Prize for deposits up to 6,000 USD | 6055096 |
2nd Prize: 3 x 300 USD Cash Prize for deposits up to 3,000 USD | 6058973 6039595 6056756 |
3rd Prize: 6 x 150 USD Cash Prize for deposits up to 1,000 USD | 6032352 6056756 6039595 6017412 6031328 6058892 |
4th Prize: 10 x 50 USD Cash Prize for deposits up to 100 USD | 6052054 6045145 6022740 6055196 6027946 6653398 6031496 6054437 6028966 6035683 |
On behalf of XM we thank all our clients for having participated in the seminar and we hope that the newly acquired knowledge will prove to be useful in their trading practices.
Below you can view a few photos taken on the premises.
Risk Warning: Your capital is at risk. Leveraged products may not be suitable for everyone. Please consider our Risk Disclosure.